Type 2 Diabetes and ADP Receptor Blocker Therapy
نویسندگان
چکیده
منابع مشابه
Type 2 Diabetes and ADP Receptor Blocker Therapy
Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patient...
متن کاملType 2 Diabetes, Iron, Exercise Therapy, Glycemic Control
Background and aims: Previous research has shown that one of the factors associated with type II diabetes and insulin resistance is impaired iron metabolism; also, one of the elemental keys in type II diabetes is regular exercise. The aim of this study was to evaluate the effect of moderate intensity body pump training on iron-related indices in women with type II diabetes. Methods: In the pr...
متن کاملInflammatory Cytokines and type 2 diabetes
Inflammatory cytokines increase in patients with type 2 diabetes (T2D) and metabolic syndrome. This review focuses on inflammatory cytokines such as C-reactive protein (CRP), tumor necrosis factor (TNF-α), and adiponectin, a cytokine produced by adipose tissue and associated with insulin sensitivity. Despite the major role of cytokines in the development of T2D, in the case of adiponectin still...
متن کاملAdenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
BACKGROUND Cardiovascular disease (CVD) is the most prevalent complication of type 2 diabetes with an estimated 65% of people with type 2 diabetes dying from a cause related to atherosclerosis. Adenosine-diphosphate (ADP) receptor antagonists like clopidogrel, ticlopidine, prasugrel and ticagrelor impair platelet aggregation and fibrinogen-mediated platelet cross-linking and may be effective in...
متن کاملAngiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
Angiotensin type 1 (AT1) receptor blocker (ARB) ameliorates progression of chronic kidney disease. Whether this protection is due solely to blockade of AT1, or whether diversion of angiotensin II from the AT1 to the available AT2 receptor, thus potentially enhancing AT2 receptor effects, is not known. We therefore investigated the role of AT2 receptor in ARB-induced treatment effects in chronic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes Research
سال: 2016
ISSN: 2314-6745,2314-6753
DOI: 10.1155/2016/6760710